Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
China Touyun Tech Group ( (HK:1332) ) just unveiled an announcement.
Touyun Biotech Group Limited has outlined a series of measures to address an audit disclaimer of opinion and alleviate going-concern uncertainties, centering on expanding its health products portfolio, strengthening distribution channels, and shoring up liquidity. The Group is rolling out new health products aimed at different customer segments, pursuing collaborations with supermarket chains and key opinion leaders, and has secured a strategic cooperation under which a sales consortium has committed to purchase at least RMB1 billion of Chlamydomonas reinhardtii products between 2026 and 2028. To reinforce its financial position, major stakeholders have deferred repayment of approximately HK$121.8 million of amounts due to them, the Company has obtained new loans totaling over HK$54 million from related parties and other lenders, is negotiating extensions on RMB150 million of existing loans, and is raising cash and recording gains through disposals of non-core assets and shareholdings in a subsidiary. These steps are intended to stabilize working capital, reduce audit qualifications, and support the Group’s operational and market expansion efforts.
The most recent analyst rating on (HK:1332) stock is a Sell with a HK$0.20 price target. To see the full list of analyst forecasts on China Touyun Tech Group stock, see the HK:1332 Stock Forecast page.
More about China Touyun Tech Group
Touyun Biotech Group Limited is a Hong Kong-listed group engaged in the biotechnology and health products sector, focusing on developing and selling new health products to a growing, health-conscious customer base. Through its subsidiary Shanxi Touyun Biotechnology Co., Ltd., the Group also produces Chlamydomonas reinhardtii and related products for distribution via domestic sales channels and strategic partners in mainland China.
Average Trading Volume: 4,867,637
Technical Sentiment Signal: Sell
Current Market Cap: HK$589.2M
Learn more about 1332 stock on TipRanks’ Stock Analysis page.